Let's Win Pancreatic CancerPancreatic

Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target (Part 2/2)

In short

Scientists at Dana-Farber Cancer Institute and the Broad Institute have mapped the structure of a three-protein complex called SMP (SHOC2-MRAS-PP1C) that helps RAS-mutated cancer cells survive. This discovery reveals physical 'pockets' in the complex that future drugs could target, offering a potential new treatment approach for pancreatic, lung, colon, and other cancers driven by RAS mutations — which account for about 30% of all human cancers.

  • •Ask your oncologist whether your tumor has a RAS or KRAS mutation, since this research is directly aimed at cancers with those mutations.
  • •If you have KRAS-mutant pancreatic cancer and are on or being considered for a MEK inhibitor, ask whether combining it with drugs targeting SHOC2 is being studied in clinical trials.
  • •Understand that blocking a single point in the RAS pathway often isn't enough — researchers are now looking at combination approaches, like pairing MEK inhibitors with SHOC2 disruption, to overcome resistance.
  • •This research is still in early (laboratory and animal) stages, so ask your care team how to stay informed about clinical trials that may follow from this type of discovery.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

On its own, SHOC2 looked like a half-cylinder, solenoid-shaped structure that didn’t have any pockets,” says Aguirre. The team delved deeper and looked at two key proteins that SHOC2 brings together. The proteins are called MRAS and PP1C, and they are part of the RAS pathway. “The three-protein structure showed us there actually are pockets and that drugs could potentially be targeted to those pockets,” Aguirre adds.

Curious about the effect of mutations in SHOC2 amino acids, the team also performed extensive mutation studies of SHOC to understand the impact of all possible single amino acid mutations on SHOC2 function. They generated data that potentially can be used to understand the role of SHOC2 in other diseases, including Noonan-like syndrome, which causes distinctive facial features and other symptoms related to development.

A Team Effort Aguirre is quick to point out that these insights into SHOC2 were only made possible through the collaborative efforts of many different experts from varying disciplines. “No one team could have done this alone,” Aguirre says. “We’re all very excited about developing drugs for this complex.

Highlights

from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.

Follow-up and Monitoring Managing Long-term Side Effects Emotional and Psychological Support Secondary Health Risks Lifestyle Changes In terms of cancer research, there’s a full-court press underway in collaborative scientific efforts targeting oncogenic RAS mutations. For decades, these mutations have been considered undruggable. The RAS signaling pathway is extraordinarily complicated.

It is also the most frequently mutated oncogene in human cancers. Approximately 30 percent of all human cancers are driven by mutations of the RAS family of genes. One member of this gene family is called KRAS, and it’s implicated in more than 90 percent of pancreatic malignancies. Cancers carrying a RAS mutation are typically highly aggressive and recurrent, sending signaling commands through the RAS pathway.

Now, in a study published in the journal Nature , scientists from Dana-Farber Cancer Institute (DFCI) and the Broad Institute of MIT and Harvard have determined the molecular structures of the RAS-pathway protein SHOC2 and two other proteins it binds. The three-protein SHOC2-MRAS-PP1C, or the so-called SMP complex, regulates the RAS signaling system and aids in the survival of cancer cells that have RAS mutations.

This finding may provide the key to new targeted therapy drugs offering pancreatic cancer patients and others the chance for longer-term survival. D. , of NewYork-Presbyterian/Weill Cornell Medical Center . “This is so promising because the RAS pathway is implicated not just in pancreatic cancer but in many other cancers like lung and colon cancer that affect millions of people in the world,” she explains.

” A Little Biochemistry Primer When we are healthy, RAS signaling is central to the seamless functioning of cell signaling networks involved in cell growth and survival. Like many cellular signaling pathways, however, mutations can arise in cancer that lead the complex cascade of signaling to go very wrong.

These mutations in the RAS gene itself, or in upstream or downstream regulators, can morph the normal cell proliferation, growth, and survival of cancer cells into dysregulated processes that lead to aggressive cancer. The best way to think of the RAS pathway is like a kind of chain reaction. Although the pathway is complex and fraught with acronyms, it is pretty straightforward.

RAS activates RAF; RAF activates MEK; MEK activates ERK; and ERK promotes irregular cell proliferation and tumor growth. But, unfortunately, what researchers have found is that blocking cancer cells at any single target in this pathway is generally not enough to halt the spread of cancer. That’s because a cancer cell turns on other nodes in the RAS pathway. Cancer can even activate parallel pathways in order to survive.

One such cancer drug aimed at a RAS pathway is called a MEK inhibitor. This drug blocks proteins called MEK1 and MEK2, which help control cell growth and survival. Blocking these proteins may help keep cancer cells from growing and may kill them. D. , began looking at MEK1/2 inhibition in more detail. The team knew MEK inhibition was a promising strategy against pancreatic cancer.

But tumors quickly acquired resistance to the drug that was tested, and there were significant toxicities associated with it. “We asked the question of what would be the best targets to inhibit in combination with a MEK inhibitor to improve the efficacy of this therapy,” says Aguirre, co-senior author of the Nature study .

To discover the answer, the team conducted a series of unbiased genome-scale genetic screens to identify novel targets that enhance the effectiveness of MEK inhibition in KRAS mutant cancer cells. “To make a long story short, we identified that knocking out or depleting the SHOC2 gene disrupted survival pathways,” Aguirre explains.

More studies showed that SHOC2 knockout in combination with MEK inhibitor treatment led to ablation of tumor growth in xenograft mice. D. , at DFCI and the Broad Institute, revealed the structure of SHOC2 and the proteins it interacts with.

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.